Langman CB, Delos Santos RB, Ghossein C, Atherton AM, Levtchenko EN, Servais A (2024) Fertility management in cystinosis: a clinical perspective
Each peptide vial typically contains 5 mg of lyophilized powder, which must be carefully mixed with bacteriostatic water to create a stable solution suitable for subcutaneous injection in research models
Integrating biomarkers into clinical practice can tailor interventions, leading to more effective management strategies
Injection site reaction (Pain, stinging, tingling, burning, redness and swelling at site of injection)
This product may contain aluminum, which may accumulate to toxic levels in patients with renal dysfunction or during high-dose or long-term treatment
Holds 1 mL, and each mark is 0.01 mL